Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;89(3):519-528.
doi: 10.1016/j.jaad.2023.04.052. Epub 2023 May 5.

Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort

Jonathan I Silverberg  1 , Brenda Simpson  2 , Katrina Abuabara  3 , Emma Guttman-Yassky  4 , Brian Calimlim  5 , Colleen Wegzyn  5 , Whitney Krueger  5 , Amy Gamelli  5 , Breda Munoz  6 , Rachel W Faller  6 , Julie M Crawford  6 , Ayman Grada  5 , Lawrence F Eichenfield  7 ; TARGET-DERM Investigators
Affiliations

Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort

Jonathan I Silverberg et al. J Am Acad Dermatol. 2023 Sep.

Abstract

Background: Atopic dermatitis (AD) is severely burdensome, and there has been poor characterization of any differences in impact based on the area affected.

Objective: To estimate the prevalence and HRQoL impact of head/face/neck/hand (HFNH) involvement among patients with moderate-to-severe atopic dermatitis.

Methods: All TARGET-DERM AD registry patients with moderate/severe Investigator Global Assessment (vIGA-AD) were assessed using the Patient Oriented SCORing Atopic Dermatitis, Patient Oriented Eczema Measure (POEM) and the (Children's) Dermatology Life Quality Index ((C)DLQI).

Results: 541 participants met the criteria (75.0% adults) and 84% (N = 453) reported HFNH involvement. HFNH and non-HFNH involved participants had similar characteristics; 55.2% female and 46.9% White. Compared to the non-HFNH involved, the involved had severe vIGA-AD (28.5% vs 16.3%, P = .02) and higher median body surface area affected (15% vs 10%, P ≤ .01) and were twice as likely to have higher (C)DLQI and POEM scores.

Limitations: This was an analysis of real-world and patient reported outcome data.

Conclusion: Real-world HFNH involved AD patients were associated with significantly worse quality of life, POEM/(C)DLQI, and more severe disease. Detailed assessments of specific areas affected by AD are needed to personalize treatment.

Keywords: Dermatology Life Quality Index (DLQI); PO-SCORAD; Patient Reported Outcomes Measurement Information System (PROMIS); Patient-Oriented Eczema Measure (POEM); adult; atopic dermatitis (AD); body surface area (BSA); burden; burden of disease; challenging; child; children's dermatology life quality index (CDLQI); difficult; disease; face; hands; head; longitudinal; neck; observational; patient reported outcome (PRO); pediatric; prevalence; quality of life (QoL); real-world; severe; treatment; vIGA-AD TARGET-DERM; visible.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Jonathan I. Silverberg, MD, PhD, MPH, FAAD, receives the following financial support: consultant and/or advisory board member for Abbvie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Pfizer. Katrina Abuabara, MD, MA, PhD receives the following financial support: consulting and speaking fees from TARGET RWE; Grants from Pfizer and Cosmetique Internacional SNC. Emma Guttman-Yassky, MD, PhD, receives the following financial support: Employee of Mount Sinai; Research funds from Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger-Igelheim, Cara Therapeutics, Celgene, Eli Lilly, Innovaderm, Kyowa Kirin, Leo Pharma, Novartis, Pfizer, and Regeneron Pharmaceuticals; consultant for AbbVie, Almirall, Amgen, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boerhinger-Ingelhiem, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, Ventyx Biosciences. Brian Calimlim, PhD receives the following financial support: Full-time employee of AbbVie Inc; May hold AbbVie, Inc, stock, or stock options. Colleen Wegzyn, PharmD receives the following financial support: Full-time employee of AbbVie Inc; May hold AbbVie, Inc, stock, or stock options.Whitney Krueger, PhD, MPH, BSc, receives the following financial support: Full-time employee of AbbVie Inc; May hold AbbVie, Inc, stock, or stock options. Amy Gamelli, PhD, receives the following financial support: Full-time employee of AbbVie Inc; May hold AbbVie, Inc, stock, or stock options. Breda Munoz, PhD, receives the following financial support: Full-time employee of Target RWE. Rachel W. Faller, PhD, receives the following financial support: Full-time employee of Target RWE. Julie M. Crawford, MD, receives the following financial support: Full-time employee of Target RWE. Ayman Grada, MD, MS, receives the following financial support: Employee of AbbVie, Inc. Lawrence F. Eichenfield receives the following financial support: Adviser or consultant for Pfizer, Inc, AbbVie, Inc, Almirall, Amgen, Arcutis, Asana Biosciences, Celgene, Cutanea, Dermavant, Dermira, Eli Lilly, Forte Biosciences, Galderma, Ichnos & Glenmark, Incyte, Kyowa Kirin, LEO Pharma, Novartis, Ortho Dermatologics & Valeant, Otsuka, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Verrica.

Publication types

LinkOut - more resources